Big Picture Bio Raises £1.5M Pre-Seed to Advance Generative World Model for Combination Therapies

Big Picture Bio Secures £1.5M Pre-Seed

London-based biotech Big Picture Bio has raised £1.5 million in pre-seed funding. The round was led by Exceptional Ventures, with participation from Kadmos Capital, Gloucester Ventures, and John White.

What Big Picture Bio Does

Big Picture Bio is developing a generative world model designed to design combination therapies for cancer and immune-mediated diseases. The platform simulates how tumours, immune cells, and surrounding tissue interact across different disease sites and patient subgroups. This approach aims to predict therapeutic outcomes before costly and time-consuming wet-lab work.

The company pairs its AI-driven modelling with targeted wet-lab validation. According to the company, its predictions have been benchmarked against real-world clinical outcomes, including data presented at ASCO.

Founders and Background

Big Picture Bio was founded in 2026 by Kerstin Papenfuss and Mark Hammond, both veterans of Deep Science Ventures. Their experience in deep science venture creation underpins the company's focus on combining computational modelling with experimental validation.

Funding Details

• Round type: Pre-Seed
• Amount raised: £1,500,000
• Lead investor: Exceptional Ventures
• Additional investors: Kadmos Capital, Gloucester Ventures, John White
• Announced date: 17 September 2026

Why This Matters for Acquisition

The intersection of generative AI and oncology drug discovery remains a high-interest area for strategic acquirers and investors. Big Picture Bio's world model approach—simulating complex biological interactions across disease sites and patient subgroups—could offer a differentiated platform for combination therapy design. The company's early benchmarking against real-world clinical outcomes, including ASCO-presented data, provides an initial validation signal.

For potential acquirers in biotech, pharma, or AI-driven drug discovery, Big Picture Bio represents an early-stage asset with a computational platform that may complement existing R&D pipelines. The pre-seed round provides initial capital to further develop the platform and expand wet-lab validation efforts.

Outlook

With fresh capital, Big Picture Bio is positioned to advance its generative world model and continue validating predictions against clinical data. The involvement of Exceptional Ventures as lead, alongside a syndicate of additional investors, suggests confidence in the team's ability to execute on a computationally intensive, biology-driven vision.